Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Dietary Supplement Division Soon May Need Office Accommodations

This article was originally published in The Tan Sheet

Executive Summary

Without an objection from Congress, FDA’s Division of Dietary Supplement Programs becomes a CFSAN office on Dec. 21. Objections or questions from one or more members are possible, but HHS likely would not make the notification without high confidence Congress would not object.

You may also be interested in...



US FDA's Dietary Supplement Programs Deserve A Raise, Trade Groups Tell Senate Appropriators

Compliant industry drove US market growth to $55bn in 2020, and faster growth and higher sales are ahead if FDA’s Office of Dietary Supplement Programs has sufficient funding to eliminate non-compliant businesses.

Next US FDA Commissioner Will Have Opening To Fill In Dietary Supplement Programs Office

Steven Tave on 15 March will move from ODSP director to lead ORA’s Office of Strategic Planning and Operational Policy. Agency’s next commissioner, who Capitol Hill lobbyists say could be named next week, will appoint a replacement.

US Supplement Market Growth: Is The Industry In Its Own Way?

Longtime supplement industry attorney Scott Bass says supplement manufacturers should work with FDA as an ally, including registering products with the agency pre-market, while FDA's second-in-command for supplement industry oversight, Robert Durkin, says the agency is not interested in preventing more safe products from reaching the market.

Related Content

Topics

UsernamePublicRestriction

Register

PS108058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel